Metastatic papillary renal cancer has poor outcomes, and new treatments are needed. There is a strong rationale for investigating the combination of mesenchymal epithelial transition receptor (MET) ...

The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

In this video, Francesca Jackson-Spence,MBChB, BSc, shares data from the study, “Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO; NCT02819596),” ...

The three most common forms of RCC are clear cell RCC, papillary RCC and chromophobe RCC. Metabolic dysregulation in the development of clear cell renal cell carcinoma (ccRCC) remains to be ...

Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 LITESPARK-003 data.

A Waukesha County sheriff’s deputy, Steve Lyles, fights a rare cancer with a positive attitude and dedication to his job. His ...

ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...

Research reveals new aspects ... Even Low Levels of Arsenic in Drinking Water Raise Kidney Cancer Risk Dec. 2, 2024 — New research findings indicate that exposure to even low levels of arsenic ...

Kidney transplant recipients who’ve never been exposed to the Epstein-Barr virus but receive organs from a donor who has been may develop a rare and aggressive cancer As many as 1,200 patients a year ...

There could be new hope on the horizon for kidney cancer patients in the form of an experimental vaccine. Researchers at Dana-Farber Cancer Institute, Harvard Medical School, Yale Cancer Center ...

There could be new hope on the horizon for kidney cancer patients in the form of an experimental vaccine. Researchers at Dana-Farber Cancer Institute, Harvard Medical School, Yale Cancer Center ...